Samsung Pharm (001360) - Total Liabilities

Latest as of September 2025: ₩44.04 Billion KRW ≈ $29.85 Million USD

Based on the latest financial reports, Samsung Pharm (001360) has total liabilities worth ₩44.04 Billion KRW (≈ $29.85 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Samsung Pharm - Total Liabilities Trend (2012–2024)

This chart illustrates how Samsung Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore Samsung Pharm (001360) long-term investment share to see how much of total assets are deployed in long-term investments.

Samsung Pharm Competitors by Total Liabilities

The table below lists competitors of Samsung Pharm ranked by their total liabilities.

Company	Country	Total Liabilities
Hanjin Heavy Ind & Const Holdings Co Ltd KO:003480	Korea	₩1.21 Trillion
Petrovietnam Low Pressure Gas Distribution JSC VN:PGD	Vietnam	₫1.84 Trillion
Pelthos Therapeutics Inc. NYSE MKT:PTHS	USA	$91.52 Million
DYO Boya Fabrikalari Sanayi ve Ticaret AS IS:DYOBY	Turkey	TL11.92 Billion
Hwaseung Industries Co Ltd KO:006060	Korea	₩1.09 Trillion
ORIENTBIO Inc. KO:002630	Korea	₩12.64 Billion
C&G Hi Tech Co.Ltd KQ:264660	Korea	₩49.24 Billion
Ann Joo Resources Bhd KLSE:6556	Malaysia	RM1.82 Billion

Liability Composition Analysis (2012–2024)

This chart breaks down Samsung Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Samsung Pharm.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.54	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.24	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.20	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Samsung Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Samsung Pharm (2012–2024)

The table below shows the annual total liabilities of Samsung Pharm from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩22.60 Billion ≈ $15.31 Million	+42.17%
2023-12-31	₩15.89 Billion ≈ $10.77 Million	+3.72%
2022-12-31	₩15.32 Billion ≈ $10.39 Million	-15.73%
2021-12-31	₩18.19 Billion ≈ $12.32 Million	-67.99%
2020-12-31	₩56.81 Billion ≈ $38.50 Million	+121.03%
2019-12-31	₩25.70 Billion ≈ $17.42 Million	-11.32%
2018-12-31	₩28.98 Billion ≈ $19.64 Million	-51.95%
2017-12-31	₩60.33 Billion ≈ $40.88 Million	+7.90%
2016-12-31	₩55.91 Billion ≈ $37.89 Million	-33.43%
2015-12-31	₩83.98 Billion ≈ $56.91 Million	+146.17%
2014-12-31	₩34.12 Billion ≈ $23.12 Million	-50.05%
2012-12-31	₩68.31 Billion ≈ $46.29 Million	--

About Samsung Pharm

KO:001360 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$85.53 Million

₩126.22 Billion KRW

Market Cap Rank

#19829 Global

#1033 in Korea

Share Price

₩1341.00

Change (1 day)

+3.00%

52-Week Range

₩1180.00 - ₩2210.00

All Time High

₩12289.83